Board Member
General Motors Co (GM)Equibles does not estimate personal net worth.
Get an email with a short summary when Crescent Biopharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get CBIO alertsJonathan McNeill is recorded as COO at Crescent Biopharma, Inc. (CBIO) and Board Member at General Motors Co (GM) since September 30, 2022. The newest filing on record that lists Jonathan McNeill as COO at Crescent Biopharma, Inc. (CBIO) is dated April 21, 2026. General Motors Co reported in an 8-K filed May 26, 2026 that Jonathan McNeill retired as member of the Board of Directors, effective June 2, 2026. Crescent Biopharma, Inc. reported in an 8-K filed July 31, 2025 that Jonathan McNeill was appointed president and chief operating officer. Crescent Biopharma, Inc. reported in an 8-K filed June 18, 2025 that Jonathan McNeill was appointed Chief Operating Officer and President, effective June 13, 2025. Equibles holds 4 filed executive changes naming Jonathan McNeill; each is listed under recent activity with its source filing. The proxy statement of Dyne Therapeutics, Inc. reports total compensation of $2,230,830 for Jonathan McNeill in fiscal 2023, including a base salary of $430,468. Jonathan McNeill has spoken on 2 investor events across 1 company, most recently for Crescent Biopharma, Inc. on September 14, 2026. Crescent Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. General Motors Co is classified in the Auto Manufacturers industry within the Consumer Cyclical sector. Other leadership on record at Crescent Biopharma, Inc. includes Joshua Brumm (CEO and Board Member), Peter Harwin (Chairman and Board Member), Richard Scalzo (CFO) and 7 others.
“On May 26, 2026, Jonathan McNeill, a member of the Board of Directors (the “Board”) of General Motors Company (the “Company”), notified the Board that he will not stand for reelection as a director at the Company’s 2026 Annual Meeting of Shareholders to be held on June 2, 2026 (the “Annual Meeting”) and will retire from the Board upon the conclusion of the Annual Meeting.”
“Crescent appointed new leadership bringing experience in oncology drug development, clinical operations and building biotech companies, including Joshua Brumm as chief executive officer and member of the board of directors; Jonathan McNeill, M.D., as president and chief operating officer; Ellie Im, M.D., as chief medical officer; Rick Scalzo, MBA, as chief financial officer; Jan Pinkas, Ph.D., as chief scientific officer; Amy Reilly as chief communications officer; and Tanya Sengupta, MBA, as executive vice president, chief of strategy and operations.”
“So the Colun partnership came together because they share our vision of synergistic combinations being the next wave of oncology therapies for many solid tumors.”
“Well, I'd say first, we don't want to get ahead of our partner, Colun, around describing what the 001 SAC-TMT study is, and we'll be excited to share more about that when that's But we're excited to generate that data because I think that will inform the question you asked, which is, is this applicable across all…”
2022-09-30–present
Start not stated–present
Last confirmed April 21, 2026
2022-01-01–2026-06-02
Proxy statement
Start not stated–2024-04-05
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
COO
Auto Manufacturers · Consumer Cyclical
Board Member
2022-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Dyne Therapeutics, Inc. (DYN) | Chief Business Officer | $430,468 | $2,230,830 |
